Imunon, Inc. (IMNN) stock
IMNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.63−0.01 (-1.22%)
Close on Nov 13, 2026Market cap $3.53MP/E –Yield –
Imunon EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Imunon's EPS for the twelve months ending Mar 31, 2026 was -$5.59. For fiscal 2025 it was -$6.83. The highest annual figure on record is -$2.16 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.83 | – |
| FY2024 | Dec 31, 2024 | -$16.94 | – |
| FY2023 | Dec 31, 2023 | -$2.16 | – |
| FY2022 | Dec 31, 2022 | -$5.03 | – |
| FY2021 | Dec 31, 2021 | -$3.83 | – |
| FY2020 | Dec 31, 2020 | -$10.08 | – |
| FY2019 | Dec 31, 2019 | -$11.55 | – |
| FY2018 | Dec 31, 2018 | -$10.20 | – |
| FY2017 | Dec 31, 2017 | -$40.80 | – |
| FY2016 | Dec 31, 2016 | -$178.35 | – |
| FY2015 | Dec 31, 2015 | -$393.98 | – |
| FY2014 | Dec 31, 2014 | -$527.85 | – |
| FY2013 | Dec 31, 2013 | -$363.38 | – |
| FY2012 | Dec 31, 2012 | -$1315.80 | – |
| FY2011 | Dec 31, 2011 | -$1912.50 | – |
| FY2010 | Dec 31, 2010 | -$2616.30 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$0.84 | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.44 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.16 | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.15 | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.15 | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.11 | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.76 | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.64 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.52 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.52 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.37 | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.52 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.87 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.87 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.82 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.73 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.90 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.90 | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.35 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.19 | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.60 | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.70 | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.00 | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.81 | -139.6% |
| Q3 FY2019 | Sep 30, 2019 | -$3.75 | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.35 | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.80 | – |
| Q4 FY2018 | Dec 31, 2018 | $4.57 | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.90 | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.90 | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.75 | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.50 | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.50 | – |
| Q1 FY2017 | Mar 31, 2017 | -$46.35 | – |
| Q3 FY2016 | Sep 30, 2016 | -$48.30 | – |
| Q2 FY2016 | Jun 30, 2016 | -$39.45 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?